Luckys Pharma Lab Private Limited

FUBONIN-100-Nintedanib Soft Gelatin Capsules 100mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC). 

FUBONIN-150-Nintedanib Soft Gelatin Capsules 150mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC). 

FUBONIN-150-Nintedanib Soft Gelatin Capsules 150mg  is a prescription medication primarily used in the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. It works by inhibiting several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By targeting these pathways, Nintedanib helps slow the progression of lung scarring, reducing the worsening of lung function in conditions like IPF. Additionally, it is used to manage non-small cell lung cancer (NSCLC) in combination with other treatments.

FUBONIN-150-Nintedanib Soft Gelatin Capsules 150mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC). 

FUBONIN-100-Nintedanib Soft Gelatin Capsules 100mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC). 

FUBONIN-150-Nintedanib Soft Gelatin Capsules 150mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC). 

FUBONIN-150-Nintedanib Soft Gelatin Capsules 150mg  is a prescription medication primarily used in the treatment of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. It works by inhibiting several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By targeting these pathways, Nintedanib helps slow the progression of lung scarring, reducing the worsening of lung function in conditions like IPF. Additionally, it is used to manage non-small cell lung cancer (NSCLC) in combination with other treatments.

FUBONIN-100-Nintedanib Soft Gelatin Capsules 100mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC). . 

FUBONIN-150-Nintedanib Soft Gelatin Capsules 150mg is a prescription medicine primarily used for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Nintedanib works mainly by the inhibition of several receptor kinases involved in the process of fibrosis, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Blocking these pathways indicates that nintedanib helps slow the progression of lung scarring and hence reduces the rate of deterioration in lung function in conditions such as IPF. It is also used in combination with other treatments in the treatment of non-small cell lung carcinoma (NSCLC).